European Association for the Study of the Liver. Electronic address eee, European association for the study of the L: EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–72.
Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American association for the study of liver diseases. Hepatology. 2022;75(4):1012–3.
Google Scholar
Gazda J, Drazilova S, Janicko M, Jarcuska P. The Epidemiology of Primary Biliary Cholangitis in European Countries: A Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol. 2021;2021:9151525.
Google Scholar
Muratori L, Parola M, Ripalti A, Robino G, Muratori P, Bellomo G, Carini R, Lenzi M, Landini MP, Albano E, et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut. 2000;46(4):553–61.
Google Scholar
Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, Guidi M, Ferri S, C DEM, Lenzi M, et al. Antinuclear antibodies giving the ‘multiple nuclear dots’ or the ‘rim-like/membranous’ patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther. 2006;24(11–12):1575–83.
Google Scholar
Granito A, Muratori P, Quarneti C, Pappas G, Cicola R, Muratori L. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Rev Mol Diagn. 2012;12(1):65–74.
Google Scholar
Granito A, Yang WH, Muratori L, Lim MJ, Nakajima A, Ferri S, Pappas G, Quarneti C, Bianchi FB, Bloch DB, et al. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol. 2010;105(1):125–31.
Google Scholar
Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E, International Autoimmune Hepatitis G. Overlap syndromes: the international autoimmune hepatitis group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54(2):374–85.
Google Scholar
Muratori P, Granito A, Pappas G, Muratori L. Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients. Hepatology. 2009;49(5):1782–3. author reply 1783.
Google Scholar
Drazilova S, Koky T, Macej M, Janicko M, Simkova D, Tsedendamba A, Komarova S, Jarcuska P. Pruritus, fatigue, osteoporosis and dyslipoproteinemia in Pbc patients: A clinician’s perspective. Gastroenterol Insights. 2024;15(2):419–32.
Gazda J, Drazilova S, Gazda M, Janicko M, Koky T, Macej M, Carbone M, Jarcuska P. Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis. Dig Liver Dis. 2022. https://doi.org/10.1016/j.dld.2022.12.010.
Gazda J, Drazilova S, Janicko M, Grgurevic I, Filipec Kanizaj T, Koller T, Bodorovska B, Bozin T, Mijic M, Rob Z, et al. Prognostic factors in primary biliary cholangitis: A retrospective study of joint Slovak and Croatian cohort of 249 patients. J Pers Med. 2021;11(6). https://doi.org/10.3390/jpm11060495.
Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Hirschfield GM, Pares A, Floreani A, Mayo MJ, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2019;71(2):357–65.
Google Scholar
Nevens F, Trauner M, Manns MP. Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases(dagger). J Hepatol. 2023;78(2):430–41.
Google Scholar
Kumagi T, Guindi M, Fischer SE, Arenovich T, Abdalian R, Coltescu C, Heathcote EJ, Hirschfield GM. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105(10):2186–94.
Google Scholar
Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, van der Meer AJ, Feld JJ, Gulamhusein A, Lammers WJ, et al. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol. 2020;115(7):1066–74.
Google Scholar
Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, et al. A Placebo-Controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631–43.
Google Scholar
Bowlus CL, Pockros PJ, Kremer AE, Pares A, Forman LM, Drenth JPH, Ryder SD, Terracciano L, Jin Y, Liberman A, et al. Long-Term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis. Clin Gastroenterol Hepatol. 2020;18(5):1170–8. e1176.
Google Scholar
Trauner M, Nevens F, Shiffman ML, Drenth JPH, Bowlus CL, Vargas V, Andreone P, Hirschfield GM, Pencek R, Malecha ES, et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol. 2019;4(6):445–53.
Google Scholar
Londono MC, Diaz-Gonzalez A. Predicting liver-related serious adverse events in patients with primary biliary cholangitis-related cirrhosis treated with obeticholic acid. Liver Int. 2022;42(11):2356–9.
Google Scholar
Kowdley KV, Hirschfield GM, Coombs C, Malecha ES, Bessonova L, Li J, Rathnayaka N, Mells G, Jones DE, Trivedi PJ, et al. COBALT: A confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls. Am J Gastroenterol. 2024. https://doi.org/10.14309/ajg.0000000000003029.
Corpechot C, Chazouilleres O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, et al. A Placebo-Controlled trial of Bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378(23):2171–81.
Google Scholar
Cancado GGL, Couto CA, Guedes LV, Braga MH, Terrabuio DRB, Cancado ELR, Ferraz MLG, Villela-Nogueira CA, Nardelli MJ, Faria LC, et al. Fibrates for the treatment of primary biliary cholangitis unresponsive to ursodeoxycholic acid: an exploratory study. Front Pharmacol. 2021;12:818089.
Google Scholar
Li C, Zheng K, Chen Y, He C, Liu S, Yang Y, Li M, Zeng X, Wang L, Zhang F. A randomized, controlled trial on Fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid. Ther Adv Chronic Dis. 2022;13:20406223221114198.
Google Scholar
Hirschfield GM, Beuers U, Kupcinskas L, Ott P, Bergquist A, Farkkila M, Manns MP, Pares A, Spengler U, Stiess M, et al. A placebo-controlled randomised trial of Budesonide for PBC following an insufficient response to UDCA. J Hepatol. 2021;74(2):321–9.
Google Scholar
Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, Levy C, Villamil A, Ladron de Guevara Cetina AL, Janczewska E et al. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med. 2024;390(9):783–794.
Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, et al. Efficacy and safety of Elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390(9):795–805.
Google Scholar
Vuppalanchi R, Caldwell SH, Pyrsopoulos N, deLemos AS, Rossi S, Levy C, Goldberg DS, Mena EA, Sheikh A, Ravinuthala R, et al. Proof-of-concept study to evaluate the safety and efficacy of Saroglitazar in patients with primary biliary cholangitis. J Hepatol. 2022;76(1):75–85.
Google Scholar
Mayo MJ, Wigg AJ, Leggett BA, Arnold H, Thompson AJ, Weltman M, Carey EJ, Muir AJ, Ling L, Rossi SJ, et al. NGM282 for treatment of patients with primary biliary cholangitis: A multicenter, randomized, Double-Blind, Placebo-Controlled trial. Hepatol Commun. 2018;2(9):1037–50.
Google Scholar
Yang C, Guo G, Li B, Zheng L, Sun R, Wang X, Deng J, Jia G, Zhou X, Cui L, et al. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion. Hepatol Int. 2023;17(1):237–48.
Google Scholar